Amiodarone is associated with adverse outcomes in patients with sustained ventricular arrhythmias upgraded to cardiac resynchronization therapy-defibrillators.
Evan C AdelsteinAndrew D AlthouseLydia DavisDavid SchwartzmanRaveen BazazSandeep K JainNorman C WangSamir F SabaPublished in: Journal of cardiovascular electrophysiology (2019)
In patients with sustained VTA and LBBB upgraded from conventional ICDs to CRT defibrillators, concomitant amiodarone use is associated with less QRS narrowing, less LVEF improvement, greater risk of death, transplant, or VAD, and similar risk of recurrent VTA.